92 completed, 14 unknown, 10 terminated, 9 recruiting. 60 Phase 3, 22 Phase 4, 17 Phase 2, 8 Phase 1, 6 Not applicable.
Follow Certolizumab Pegol: new trials by email Literature Review of Certolizumab Pegol trials Research Report on Certolizumab Pegol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission Tociliuzumab, Infliximab, Adalimumab - Takayasu Arteritis | Not applicable | Recruiting | Marmara University | 40 | 2025-06-15 | 2026-03-25 |
| Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel Disease This is an observational study with no intervention. Patients will receive anti- TNF therapy as part of their standard care - IBD (Inflammatory Bowel Disease), Crohn Disease (CD) | Recruiting | Shmuel Kivity, MD | 40 | 2025-01-04 | 2026-06-12 | |
| Certolizumab in Recurrent Implantation Failure (RIF) Certolizumab (CIMZIA® ; TNF-α antagonist), Placebo (NaCl 0.9 % solution) - Recurrent Unexplained Implantation Failure | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 161 | 2023-11-30 | 2023-12-11 |
| Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success Ozanimod, TNF Inhibitor, Steroids - Ulcerative Colitis | Unknown | Insel Gruppe AG, University Hospital Bern | 240 | 2023-09-06 | 2023-12-06 | |
| A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis Placebo, Nipocalimab, Certolizumab - Arthritis, Rheumatoid | Phase 2 | Completed | Janssen Research & Development, LLC | 103 | 2023-08-15 | 2025-10-16 |
| The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients Anti-TNF, JAK inhibitor - Rheumatoid Arthritis | Phase 3 | Withdrawn | Abu Dhabi Stem Cells Center | 2023-03-01 | 2025-10-06 | |
| Stand UP to Rheumatoid Arthritis (SUPRA) TNFi, Anti-IL6, JAKi - Rheumatoid Arthritis | Not applicable | Recruiting | Marie Hudson, MD | 75 | 2023-02-01 | 2026-02-03 |
| Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery Cisplatin, Pemetrexed, Gemcitabine - Lung Cancer, Lung Cancer Stage II | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2022-10-19 | 2026-10-02 |
| Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis Discontinuation of biological/targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD) - Rheumatoid Arthritis | Not applicable | Unknown | Medical University of Vienna | 85 | 2022-03-01 | 2021-11-15 |
| Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis Tapered doses of TNFi, Standard dose of TNFi - Axial Spondyloarthritis | Phase 4 | Unknown | University Health Network, Toronto | 15 | 2021-12-01 | 2024-01-17 |
| COVID-19 VaccinE Response in Rheumatology Patients Upadacitinib, Abatacept, Secukinumab - Rheumatoid Arthritis, Psoriatic Arthritis | Phase 4 | Completed | Jeffrey Curtis | 841 | 2021-11-15 | 2025-05-02 |
| The Clinical Features and Pregnancy Outcomes of RA Patients Prednisone, Hydroxychloroquine, CertolizumabPegol injection - Rheumatoid Arthritis, Pregnancy Related | Unknown | Qilu Hospital of Shandong University | 100 | 2021-07-30 | 2022-12-15 | |
| A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease Certolizumab pegol, Adalimumab, Placebo - Crohn's Disease | Phase 3 | Withdrawn | UCB Biopharma SRL | 2021-06-01 | 2021-06-23 | |
| Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints Tofacitinib, TNF Inhibitor - Rheumatoid Arthritis | Completed | Brigham and Women's Hospital | 105711 | 2021-03-10 | 2022-06-22 | |
| Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints Tofacitinib, TNF Inhibitor - Rheumatoid Arthritis | Completed | Brigham and Women's Hospital | 105711 | 2021-02-22 | 2022-03-02 | |
| A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis Certolizumab pegol - Rheumatoid Arthritis | Phase 1 | Completed | UCB Biopharma SRL | 33 | 2021-02-11 | 2024-02-12 |
| Treatment of Pregnancy RA Certolizumab Pegol 200 MG/ML [Cimzia], Hydroxychloroquine, Prednisone - Rheumatoid Arthritis, Pregnancy Related | Not applicable | Unknown | RenJi Hospital | 100 | 2020-12-01 | 2020-10-01 |
| Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis Prednisolone, Sulfasalazine, Leflunomide - Psoriatic Arthritis, Withdrawal | Phase 3 | Unknown | University of Erlangen-Nürnberg Medical School | 270 | 2020-10-19 | 2022-11-14 |
Showing 20 of 132. Sign in to see all of them.
Arthritis, Rheumatoid (68) · Crohn Disease (33) · Arthritis, Psoriatic (9) · Psoriasis (7) · Spondylitis, Ankylosing (7) · Axial Spondyloarthritis (6) · Inflammatory Bowel Diseases (6) · Arthritis (5) · Colitis, Ulcerative (4) · Spondylarthritis (4) · Joint Diseases (3) · Spondylarthropathies (3) · Anemia, Dyserythropoietic, Congenital (2) · Arthritis, Juvenile (2) · Autoimmune Diseases (2)
UCB Pharma (36) · UCB Biopharma SRL (8) · UCB BIOSCIENCES GmbH (6) · UCB Pharma SA (6) · UCB Biopharma S.P.R.L. (5) · Astellas Pharma Inc (4) · Brigham and Women's Hospital (3) · UCB BIOSCIENCES, Inc. (3) · University of Erlangen-Nürnberg Medical School (3) · Karolinska Institutet (2) · Korea Otsuka Pharmaceutical Co., Ltd. (2) · Memorial Sloan Kettering Cancer Center (2) · Otsuka Pharmaceutical Co., Ltd. (2) · Shafran Gastroenterology Center (2) · UCB Celltech (2)
United States (67) · Canada (30) · Germany (30) · Czechia (23) · France (23) · Poland (23) · Belgium (17) · Italy (17) · Hungary (16) · United Kingdom (16) · Netherlands (15) · Austria (14) · Spain (13) · Australia (12) · Russia (12)
Ira Shafran, M.D. (2) · Katsuhisa Saito (2) · Ronald van Vollenhoven, MD, Prof. (2) · Ayal Hirsch, MD (1) · Benjamin Misselwitz, Prof. (1) · Bincy P. Abraham, MD, MS (1) · Bogdan Batko, MD, PhD (1) · Carlo M Taboada, MD (1) · Charles W Randall, MD (1) · Christian Dejaco, MD, PhD (1) · Christopher Ritchlin, MD / MPH (1) · Costantino Pitzalis, MD PhD FRCP (1)
PMID 29246162, PMID 32100960, PMID 32531798, PMID 17634466, PMID 19015207, PMID 19877104, PMID 20547658, PMID 21484766, PMID 22413944, PMID 22589265, PMID 26238672, PMID 26353833, PMID 27165179, PMID 27696727, PMID 28376912, PMID 28666080, PMID 29030361, PMID 29660421, PMID 32652544, PMID 36509889, PMID 40256636, PMID 42263998, PMID 17634458, PMID 17634459, PMID 18071721, PMID 18343277, PMID 18975346, PMID 19015206, PMID 19222413, PMID 19471252, PMID 19909548, PMID 20117244, PMID 20298497, PMID 20363366, PMID 20451663, PMID 20491747, PMID 20799264, PMID 21083671, PMID 21223344, PMID 21362764, PMID 21415050, PMID 21443536, PMID 21485024, PMID 21642014, PMID 21884592, PMID 22231904, PMID 22344576, PMID 22525883, PMID 22596211, PMID 22923753
2014 (9), 2005 (7), 2009 (4), 2015 (2), 2004 (1), 2008 (1), 2016 (1), 2017 (1), 2023 (1), R01HL127118 (1)